APA (7th ed.) Citation

Le Tourneau, C., Ghiringhelli, F., Saada, E., Chaltiel, R., Vansteene, D., Durando, X., . . . Filleron, T. (2023). 923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial. Annals of Oncology, 34, S583. https://doi.org/10.1016/j.annonc.2023.09.2067

Chicago Style (17th ed.) Citation

Le Tourneau, C., et al. "923P Phase II Trial Evaluating the Efficacy of Pembrolizumab Combined with Vorinostat in Patients with Recurrent And/or Metastatic Head & Neck Squamous Cell Carcinoma – Subgroup Analysis of the PEVOsq Basket Trial." Annals of Oncology 34 (2023): S583. https://doi.org/10.1016/j.annonc.2023.09.2067.

MLA (9th ed.) Citation

Le Tourneau, C., et al. "923P Phase II Trial Evaluating the Efficacy of Pembrolizumab Combined with Vorinostat in Patients with Recurrent And/or Metastatic Head & Neck Squamous Cell Carcinoma – Subgroup Analysis of the PEVOsq Basket Trial." Annals of Oncology, vol. 34, 2023, p. S583, https://doi.org/10.1016/j.annonc.2023.09.2067.